Aardvark Therapeutics (NASDAQ:AARD) Price Target Raised to $26.00

Aardvark Therapeutics (NASDAQ:AARD) had its price objective upped by Bank of America from $22.00 to $26.00 in a research note released on Thursday morning, MarketBeat Ratings reports. The brokerage currently has a buy rating on the stock.

Other research analysts also recently issued research reports about the stock. Morgan Stanley initiated coverage on Aardvark Therapeutics in a research report on Monday, March 10th. They set an “overweight” rating and a $29.00 price objective for the company. Royal Bank of Canada started coverage on shares of Aardvark Therapeutics in a research note on Monday, March 10th. They issued an “outperform” rating and a $21.00 price target on the stock. Finally, Cantor Fitzgerald started coverage on shares of Aardvark Therapeutics in a research report on Monday, March 10th. They set an “overweight” rating and a $50.00 price objective for the company.

Aardvark Therapeutics Stock Performance

Shares of AARD opened at $7.74 on Thursday. Aardvark Therapeutics has a fifty-two week low of $7.74 and a fifty-two week high of $19.58.

Insider Buying and Selling

In other Aardvark Therapeutics news, CFO Nelson Sun purchased 10,000 shares of the stock in a transaction dated Friday, February 14th. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $160,000.00. Following the completion of the transaction, the chief financial officer now directly owns 99,484 shares of the company’s stock, valued at $1,591,744. This trade represents a 11.18 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Tien-Li Lee purchased 16,542 shares of the company’s stock in a transaction on Friday, February 14th. The shares were bought at an average cost of $16.00 per share, with a total value of $264,672.00. Following the transaction, the chief executive officer now directly owns 1,496,175 shares of the company’s stock, valued at $23,938,800. This represents a 1.12 % increase in their position. The disclosure for this purchase can be found here.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.